研究概要
卵巢癌(OC)是一种特别致命的妇科恶性肿瘤,由于诊断时多为晚期、广泛的遗传异质性以及频繁对现有疗法产生耐药性,其治疗选择很少。
中文摘要
卵巢癌(OC)是一种特别致命的妇科恶性肿瘤,由于诊断时多为晚期、广泛的遗传异质性以及对现有疗法频繁产生耐药性,其治疗选择很少。免疫疗法已经彻底改变了许多实体瘤的治疗管理和临床结局,但其对OC的临床获益有限,部分原因是极度免疫抑制的肿瘤微环境(TME)以及多样且重叠的免疫逃逸机制。在这篇综述中,我们对卵巢癌的新一代免疫治疗策略进行了全面且及时的整合,强调克服免疫抑制性肿瘤微环境和提高临床应答率的策略。我们描述了OC中新兴的免疫逃逸分子机制,包括抗原呈递改变、T细胞活化抑制(例如通过免疫检查点、代谢重编程)、肿瘤相关巨噬细胞(TAMs)极化以及自然杀伤(NK)细胞功能障碍。我们还批判性地审视了几种新兴的治疗方法,包括联合免疫检查点阻断(ICB)、双特异性T细胞衔接器(BiTEs)、基于新抗原的疫苗、嵌合抗原受体(CAR)-T细胞和CAR-NK细胞疗法、溶瘤病毒(OVs)以及纳米颗粒介导的免疫调节。此外,我们重点介绍了卵巢癌肿瘤微环境靶向治疗的最新进展,聚焦于调节非淋巴细胞成分的策略,如癌症相关成纤维细胞(CAFs)、缺氧驱动信号以及PI3K/AKT/mTOR轴,以增强抗肿瘤免疫应答。最后,我们讨论预测性生物标志物、多组学系统和患者来源的类器官模型如何加速OC精准免疫疗法的开发和部署。我们想强调下一代免疫疗法的转化前景,并确定可用于在OC中实现持久应答的新分子靶点。
展开英文摘要原文
Ovarian cancer (OC) is a particularly lethal gynecological malignancy with few treatment options due to its late-stage diagnosis, extensive genetic heterogeneity, and frequent development of resistance to existing therapies. Immunotherapy has revolutionized the management and clinical outcome of numerous solid tumors, but its clinical benefit for OC has been limited, in part due to an extremely immunosuppressive tumor microenvironment (TME) and diverse, overlapping immune evasion mechanisms. In this review, we present a comprehensive and timely synthesis of next-generation immunotherapeutic approaches for ovarian cancer, emphasizing strategies that overcome the immunosuppressive tumor microenvironment and improve clinical responsiveness. We describe the emerging molecular mechanisms of immune evasion in OC, including altered antigen presentation, inhibition of T-cell activation (e.g., via immunological checkpoints, metabolic reprogramming), polarization of tumor-associated macrophages (TAMs), and dysfunction of natural killer (NK) cells. We also critically examine several emerging therapeutic approaches, including combination immune checkpoint blockade (ICB), bispecific T-cell engagers (BiTEs), neoantigen-based vaccines, chimeric antigen receptor (CAR)-T- and CAR-NK-cell therapies, oncolytic viruses (OVs), and nanoparticle-mediated immunomodulation. In addition, we highlight recent advances in tumor microenvironment-targeted therapies for ovarian cancer, focusing on strategies that modulate non-lymphoid components such as cancer-associated fibroblasts (CAFs), hypoxia-driven signaling, and the PI3K/AKT/mTOR axis to enhance antitumor immune responsiveness. Finally, we discuss how predictive biomarkers, multi-omics systems, and patient-derived organoid models are accelerating the development and deployment of precision immunotherapies for OC. We would like to highlight the translational promise of next-generation immunotherapies and identify novel molecular targets that may be leveraged to achieve durable responses in OC.
论文信息
- 作者
- Rahman MA、Jalouli M、Al-Zharani M、Harrath AH
- 第一作者单位
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.United States
- 通讯作者单位
- Zoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.Saudi Arabia
- 文献类型
- 综述
- 期刊
- Biomolecules2026 Feb 4